The role of PET/CT in the central nervous system tumours
The appearance of hybrid imaging, including PET/CT has been a huge milestone not only in the development of nuclear medicine but of the whole medical imaging. The examination with 18F-FDG, the most frequently used radiopharmaceutical has become for now one of the most important diagnostic tools in oncological patient care, applied with numerous indication goals. However, the depiction of central nervous system malignancies, especially those of the brain, with FDG PET has limitations due to high cerebral background activity, it can be used primarily in lymphoma cases. To evaluate gliomas and brain metastases, amino acid tracers (11C-methionine, 18F-DOPA and 18F-FET) gained ground, which reflect other biological processes compared to that of FDG. Upon multiplying of evidences their usage is becoming more and more diverse, from the primary assessment of brain tumours (benign vs. malignant), through their grading and evaluation of posttherapeutical viability/recurrence, up to the radiotherapy planning. This paper reviews all of these in more details, mentioning shortly the prospects and challenges of the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Magyar onkologia - 67(2023), 4 vom: 18. Dez., Seite 321-331 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A PET-CT szerepe a központi idegrendszeri daganatokban |
|---|
| Beteiligte Personen: |
Szabó, Péter [VerfasserIn] |
|---|
| Themen: |
0Z5B2CJX4D |
|---|
| Anmerkungen: |
Date Completed 20.12.2023 Date Revised 20.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM366002082 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366002082 | ||
| 003 | DE-627 | ||
| 005 | 20231227134936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n1233.xml |
| 035 | |a (DE-627)NLM366002082 | ||
| 035 | |a (NLM)38109511 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Szabó, Péter |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of PET/CT in the central nervous system tumours |
| 246 | 3 | 3 | |a A PET-CT szerepe a központi idegrendszeri daganatokban |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2023 | ||
| 500 | |a Date Revised 20.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The appearance of hybrid imaging, including PET/CT has been a huge milestone not only in the development of nuclear medicine but of the whole medical imaging. The examination with 18F-FDG, the most frequently used radiopharmaceutical has become for now one of the most important diagnostic tools in oncological patient care, applied with numerous indication goals. However, the depiction of central nervous system malignancies, especially those of the brain, with FDG PET has limitations due to high cerebral background activity, it can be used primarily in lymphoma cases. To evaluate gliomas and brain metastases, amino acid tracers (11C-methionine, 18F-DOPA and 18F-FET) gained ground, which reflect other biological processes compared to that of FDG. Upon multiplying of evidences their usage is becoming more and more diverse, from the primary assessment of brain tumours (benign vs. malignant), through their grading and evaluation of posttherapeutical viability/recurrence, up to the radiotherapy planning. This paper reviews all of these in more details, mentioning shortly the prospects and challenges of the future | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Magyar onkologia |d 1961 |g 67(2023), 4 vom: 18. Dez., Seite 321-331 |w (DE-627)NLM092654185 |x 2060-0399 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2023 |g number:4 |g day:18 |g month:12 |g pages:321-331 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2023 |e 4 |b 18 |c 12 |h 321-331 | ||